ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2026
[Research advances in immune and metabolic dysregulation in the diagnosis and treatment of acute-on-chronic liver failure].
Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Acute-on-chronic liver failure (ACLF) has rapid onset and progression, with an extremely high short-term mortality rate. Accurate assessment and early intervention are crucial in clinical diagnosis and treatment. The core pathophysiological mechanisms of ACLF involve immune and metabolic dysregulation, which do not occur in isolation but instead interact through an "immune-metabolic interaction axis," mutually driving each other and evolving dynamically. Immune dysregulation is characterized by a dynamic transition from a systemic hyperinflammatory state to immunosuppression, whereas metabolic dysregulation is centered on mitochondrial dysfunction, triggering the reprogramming of multiple metabolic pathways. The interplay between these processes creates a vicious cycle that collectively drives disease progression. In recent years, with the deepening of mechanism research, various immune-and metabolic-related biomarkers have been identified and gradually applied in clinical evaluation and treatment. This article systematically reviews the current research status of immune and metabolic dysregulation in patients with ACLF and explores the potential application prospects of related biomarkers in diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.